leisure time -WSS

leisure time

author：entertainment 2025-08-23 18:38:05 - browse：9717

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Wikipedia

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

FTC loses bid to block Novant's North Carolina hospital merger

Sanofi seeks simpler, safer CRISPR sickle cell cure

An outdated Medicare rule harms dementia patients with anxiety

Data don't support strong claims for Covid

Senators tussle over abortion against the backdrop of a presidential campaign

knowledge

leisure time

focus

Supreme Court strikes down use of affirmative action

Listen: Wegovy in the brain & pivotal Alzheimer's data

Medicare proposal to cover medical devices draws a mixed reaction

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Duchenne breakthrough therapy leaves behind pioneering families

Why hospitals are withdrawing from US News rankings

Drug repurposing or repositioning? The language matters

Doctors find melanoma drugs effective against rare brain cancer

Alkermes shareholders re

Elevance PBM president out as customers face prescription chaos

focus

Cosmetics set for new safety regulation. Why the industry is on board

Group opposing PBM reform sets lobbying record

Google and Epic fight stronger regulation of AI in health care

Structure Therapeutics oral GLP

An outdated Medicare rule harms dementia patients with anxiety

How CO2 helps viruses stay alive longer in the air

focus

Wikipedia

focus

hotspot